Literature DB >> 23291536

Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.

Sophie Parmentier-Batteur1, Peter H Hutson2, Karsten Menzel2, Jason M Uslaner2, Britta A Mattson2, Julie A O'Brien2, Brian C Magliaro2, Thomas Forest2, Craig A Stump2, Robert M Tynebor2, Neville J Anthony2, Thomas J Tucker2, Xu-Fang Zhang2, Robert Gomez2, Sarah L Huszar2, Nathalie Lambeng3, H Fauré3, Emannuel Le Poul3, Sonia Poli3, Thomas W Rosahl2, Jean-Philippe Rocher3, Richard Hargreaves2, Theresa M Williams2.   

Abstract

Previous work has suggested that activation of mGlu5 receptor augments NMDA receptor function and thereby may constitute a rational approach addressing glutamate hypofunction in schizophrenia and a target for novel antipsychotic drug development. Here, we report the in vitro activity, in vivo efficacy and safety profile of 5PAM523 (4-Fluorophenyl){(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl}methanone), a structurally novel positive allosteric modulator selective of mGlu5. In cells expressing human mGlu5 receptor, 5PAM523 potentiated threshold responses to glutamate in fluorometric calcium assays, but does not have any intrinsic agonist activity. 5PAM523 acts as an allosteric modulator as suggested by the binding studies showing that 5PAM523 did not displace the binding of the orthosteric ligand quisqualic acid, but did partially compete with the negative allosteric modulator, MPyEP. In vivo, 5PAM523 reversed amphetamine-induced locomotor activity in rats. Therefore, both the in vitro and in vivo data demonstrate that 5PAM523 acts as a selective mGlu5 PAM and exhibits anti-psychotic like activity. To study the potential for adverse effects and particularly neurotoxicity, brain histopathological exams were performed in rats treated for 4 days with 5PAM523 or vehicle. The brain exam revealed moderate to severe neuronal necrosis in the rats treated with the doses of 30 and 50 mg/kg, particularly in the auditory cortex and hippocampus. To investigate whether this neurotoxicity is mechanism specific to 5PAM523, similar safety studies were carried out with three other structurally distinct selective mGlu5 PAMs. Results revealed a comparable pattern of neuronal cell death. Finally, 5PAM523 was tested in mGlu5 knock-out (KO) and wild type (WT) mice. mGlu5 WT mice treated with 5PAM523 for 4 days at 100 mg/kg presented significant neuronal death in the auditory cortex and hippocampus. Conversely, mGlu5 KO mice did not show any neuronal loss by histopathology, suggesting that enhancement of mGlu5 function is responsible for the toxicity of 5PAM523. This study reveals for the first time that augmentation of mGlu5 function with selective allosteric modulators results in neurotoxicity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antipsychotic activity; Metabotropic glutamate receptor; Neurotoxicity; Positive allosteric modulator; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23291536     DOI: 10.1016/j.neuropharm.2012.12.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  38 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

Review 2.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

3.  Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.

Authors:  Susana Conde-Ceide; Carlos M Martínez-Viturro; Jesús Alcázar; Pedro M Garcia-Barrantes; Hilde Lavreysen; Claire Mackie; Paige N Vinson; Jerri M Rook; Thomas M Bridges; J Scott Daniels; Anton Megens; Xavier Langlois; Wilhelmus H Drinkenburg; Abdellah Ahnaou; Colleen M Niswender; Carrie K Jones; Gregor J Macdonald; Thomas Steckler; P Jeffrey Conn; Shaun R Stauffer; José Manuel Bartolomé-Nebreda; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2015-05-20       Impact factor: 4.345

4.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

5.  Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.

Authors:  V D'Amore; I Santolini; R Celli; L Lionetto; A De Fusco; M Simmaco; C M van Rijn; E Vieira; S R Stauffer; P J Conn; P Bosco; F Nicoletti; G van Luijtelaar; R T Ngomba
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

6.  Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.

Authors:  Jerri M Rook; Zixiu Xiang; Xiaohui Lv; Ayan Ghoshal; Jonathan W Dickerson; Thomas M Bridges; Kari A Johnson; Daniel J Foster; Karen J Gregory; Paige N Vinson; Analisa D Thompson; Nellie Byun; Rebekah L Collier; Michael Bubser; Michael T Nedelcovych; Robert W Gould; Shaun R Stauffer; J Scott Daniels; Colleen M Niswender; Hilde Lavreysen; Claire Mackie; Susana Conde-Ceide; Jesus Alcazar; José M Bartolomé-Nebreda; Gregor J Macdonald; John C Talpos; Thomas Steckler; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuron       Date:  2015-04-30       Impact factor: 17.173

7.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Authors:  Karen J Gregory; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2015-03-25       Impact factor: 4.436

8.  Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.

Authors:  Chrysa Malosh; Mark Turlington; Thomas M Bridges; Jerri M Rook; Meredith J Noetzel; Paige N Vinson; Thomas Steckler; Hilde Lavreysen; Claire Mackie; José M Bartolomé-Nebreda; Susana Conde-Ceide; Carlos M Martínez-Viturro; María Piedrafita; M Rosa Sánchez-Casado; Gregor J Macdonald; J Scott Daniels; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2015-10-09       Impact factor: 2.823

Review 9.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

10.  Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5.

Authors:  Fukang Yang; Lawrence B Snyder; Anand Balakrishnan; Jeffrey M Brown; Digavalli V Sivarao; Amy Easton; Alda Fernandes; Michael Gulianello; Umesh M Hanumegowda; Hong Huang; Yanling Huang; Kelli M Jones; Yu-Wen Li; Michele Matchett; Gail Mattson; Regina Miller; Kenneth S Santone; Arun Senapati; Eric E Shields; Frank J Simutis; Ryan Westphal; Valerie J Whiterock; Joanne J Bronson; John E Macor; Andrew P Degnan
Journal:  ACS Med Chem Lett       Date:  2016-01-04       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.